Physician profile
Brandi Addison
NPI 1891115275
$646,952.11
in general payments reported to CMS, 2019-2025
56 companies · $147K in 2025
The $147K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $62K · 2021: $85K · 2022: $104K · 2023: $95K · 2024: $140K · 2025: $147K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $303K · Travel and Lodging: $39K · Honoraria: $15K · Food and Beverage: $14K · Consulting Fee: $12K · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $303,012.14 |
| Travel and Lodging | $38,936.86 |
| Honoraria | $15,175.00 |
| Food and Beverage | $13,547.23 |
| Consulting Fee | $11,650.00 |
| Education | $105.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $330,391.70 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Corcept Therapeutics | $149,658.41 | 2019-2025 | Korlym |
| Novo Nordisk INC | $97,569.47 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Eli Lilly and Company | $18,121.27 | 2024-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $18,030.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $17,784.49 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,001.25 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $838.41 | 2019-2025 | Tepezza, Repatha, Evenity |
| Dexcom, INC. | $460.02 | 2021-2024 | Dexcom G6 Transmitter |
| Senseonics, Incorporated | $400.00 | 2023 | Eversense |
| Abbott Laboratories | $382.63 | 2020-2025 | Freestyle Libre |
| Novartis Pharmaceuticals Corporation | $374.56 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $346.41 | 2023-2025 | |
| Amarin Pharma, INC. | $311.47 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $308.16 | 2019-2024 | Keytruda |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $302.11 | 2020-2023 | Nocdurna, Tlando, Xyosted |
| Nevro Corp. | $270.39 | 2022-2023 | Senza |
| Xeris Pharmaceuticals, INC. | $228.86 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $176.36 | 2019-2025 | Omnipod |
| Madrigal Pharmaceuticals | $174.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $170.67 | 2021-2025 | Synchromedii |
| Tandem Diabetes Care, INC. | $145.54 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $131.45 | 2021-2025 | Nexletol |
| Ascendis Pharma Endocrinology INC | $129.25 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $124.84 | 2024-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $101.77 | 2023-2025 | Ubrelvy, Synthroid |
| Ibsa Pharma INC. | $97.54 | 2019-2025 | Tirosint, Licart, Flector |
| Neurocrine Biosciences, INC. | $85.96 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $71.38 | 2025 | Unithroid |
| Mannkind Corporation | $62.02 | 2023-2025 | Afrezza |
| Ascensia Diabetes Care US INC. | $52.24 | 2023-2024 | |
| Henry Schein, INC. | $49.96 | 2024 | |
| Averitas Pharma INC. | $47.84 | 2023 | Qutenza |
| Astellas Pharma US INC | $45.00 | 2019 | |
| Medtronic Minimed, INC. | $43.70 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $43.56 | 2020-2023 | |
| Rhythm Pharmaceuticals, INC. | $41.07 | 2023 | Imcivree |
| Glaxosmithkline, LLC. | $34.08 | 2019-2025 | Arexvy, Shingrix |
| Sequel Med Tech, LLC | $31.99 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $30.61 | 2019 | |
| Incyte Corporation | $30.40 | 2021 | |
| Currax Pharmaceuticals LLC | $29.38 | 2022-2023 | Contrave |
| Blueprint Medicines Corporation | $23.66 | 2023 | Ayvakit |
| Chiesi USA, INC. | $22.53 | 2024 | Mycapssa |
| Halozyme INC | $22.19 | 2023 | |
| Beta Bionics, INC. | $20.80 | 2024 | Ilet Bionic Pancreas |
| Pfizer INC. | $17.57 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $16.71 | 2021 | |
| Radius Health, INC. | $15.80 | 2023 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $15.71 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.58 | 2020 | |
| Shire North American Group INC | $13.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.63 | 2022 | |
| Endo Pharmaceuticals INC. | $13.59 | 2019 | |
| Cequr Corporation | $10.61 | 2023 | Cequr Simplicity |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Addison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.